

À des fins de recherche uniquement

# Anticorps Monoclonal anti-SMYD3

Numéro de catalogue: 66330-1-Ig



## Informations de base

Numéro de catalogue:	BC031010	Méthode de purification:
66330-1-Ig		Purification par protéine G
Taille:	Identification du gène (NCBI):	CloneNo.:
150ul , Concentration: 1700 µg/ml by Nanodrop and 1000 µg/ml by Bradford method using BSA as the standard;	64754 Nom complet: SET and MYND domain containing 3	1B5C10
Hôte:	MW calculé	Dilutions recommandées:
Mouse	428aa,49 kDa; 369aa,42 kDa	WB 1:500-1:2000 IHC 1:50-1:500 IF 1:200-1:800
Isotype:	MW observés:	
IgG1	49 kDa	
Immunogen Catalog Number:		
AG2624		

## Applications

Applications testées:	Contrôles positifs:
IF, IHC, WB, ELISA	WB : cellules A431, cellules COLO 320, cellules HEK-293, cellules MCF-7
Spécificité de l'espèce:	IHC : tissu de cancer du pancréas humain, tissu de cancer du foie humain
Humain	IF : cellules MCF-7,
<b>Remarque-IHC: il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9,0; (*) À défaut, le démasquage de l'antigène peut être effectué avec un tampon citrate pH 6,0.</b>	

## Informations générales

SMYD3, also name as ZMYND1 and ZNFN3A1, belongs to the histone-lysine methyltransferase family. It is a histone methyltransferase that plays an important role in transcriptional regulation in human carcinogenesis. It can specifically methylate histone H3 at lysine 4 and activate the transcription of a set of downstream genes, including several oncogenes (e.g., N-myc, Crkl, Wnt10b, RIZ and hTERT) and genes involved in the control of cell cycle. (PMID: 20957523). It plays an important role in transcriptional activation as a member of an RNA polymerase complex. SMYD3 is frequently overexpressed in different types of cancer cells. It functions as a coactivator of Era and potentiates Era activity in response to ligand. SMYD3 as a new coactivator for ER-mediated transcription, providing a possible link between SMYD3 overexpression and breast cancer. (PMID: 19509295) The common variable number of tandem repeats polymorphism in SMYD3 is a susceptibility factor for some types of human cancer (PMID: 16155568). Mainly cytoplasmic when cells are arrested at G0/G1, accumulates in the nucleus at S phase and G2/M (Uniprot).

## Stockage

**Stockage:**  
Stocker à -20°C. Stable pendant un an après l'expédition.  
**Tampon de stockage:**  
PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3  
L'aliquotage n'est pas nécessaire pour le stockage à -20°C


\*\*\* Les 20ul contiennent 0,1% de BSA.

For technical support and original validation data for this product please contact:  
T: 1(888) 4PTGLAB (1-888-478-4522) (toll free  
in USA), or 1(312) 455-8498 (outside USA)


E: proteintech@ptglab.com  
W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


## Données de validation sélectionnées



Immunofluorescent analysis of (-20°C Ethanol) fixed MCF-7 cells using SMYD3 antibody (66330-1-Ig, Clone: 1B5C10) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L), (CL594-Phalloidin, red).



A431 cells were subjected to SDS PAGE followed by western blot with 66330-1-Ig (SMYD3 Antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.



Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 66330-1-Ig (SMYD3 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).